Skip to main content
Canadian Medical Association Journal logoLink to Canadian Medical Association Journal
. 1976 Dec 18;115(12):1205–1208.

Canadian clinical trial of antilymphocyte globulin in human cadaver renal transplantation.

H E Taylor, C F Ackman, I Horowitz
PMCID: PMC1878972  PMID: 793705

Abstract

A multicentre, randomized clinical trial of antilymphocyte globulin (ALG) was conducted among patients who had undergone cadaver kidney transplantation; follow-up was continued for a minimum of 1 year. Of the 179 patients 92 were given conventional treatment only, while 87 were given in addition ALG (from a standardized, highly immunosuppressive, common pool of equine ALG), 20 mg/kg-d intravenously for 10 days after transplantation. The ALG-treated group had better accumulated graft survival, fewer nephrectomies, better graft function, less than half the number of acute rejection episodes and less prednisone use. There was a beneficial drug (ALG)-related effect in both the graft and the host during the first 3 months after transplantation.

Full text

PDF
1208

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Najarian J. S., Simmons R. L. The clinical use of antilymphocyte globulin. N Engl J Med. 1971 Jul 15;285(3):158–166. doi: 10.1056/NEJM197107152850310. [DOI] [PubMed] [Google Scholar]
  2. Taylor H. E. The clinical application of antilymphocyte globulin. Med Clin North Am. 1972 Mar;56(2):419–432. doi: 10.1016/s0025-7125(16)32405-1. [DOI] [PubMed] [Google Scholar]
  3. Wilson S., Laurie G., Logan L. Standardized horse antihuman lymphocyte globulin for clinical use. Transplantation. 1973 Nov;16(5):466–475. doi: 10.1097/00007890-197311000-00011. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES